Interviews | Page 9

the-challenges-of-treating-behavioral-health-conditions
Theodore Pikoulas, PharmD, BCPP, the Associate Director of Behavioral Health Pharmacy Programs for Community Care of North Carolina, discusses the challenges that pharmacists face when treating behavioral health conditions.
how-can-pharmacists-optimize-heart-failure-patient-outcomes-following-discharge
Sneha Srivastava, PharmD, BCACP, discusses how pharmacists can work toward improving outcomes for patients recently discharged after heart failure.
new-and-emerging-therapies-to-treat-heart-failure
Sneha Srivastava, PharmD, BCACP, discusses the new and emerging therapies to treat heart failure.
can-pharmacists-dispensing-naloxone-without-a-prescription-help-reduce-fatal-outcomes
Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP, discusses whether or not allowing pharmacists to dispense naloxone without a prescription can help reduce fatal outcomes.
combating-the-stigmas-of-mental-illness
Theodore Pikoulas, PharmD, BCPP, the Associate Director of Behavioral Health Pharmacy Programs for Community Care of North Carolina, discusses how pharmacists can combat the stigmas associated with mental illness.
the-role-of-the-pharmacist-at-time-of-discharge-for-heart-failure-patients
Sneha Srivastava, PharmD, BCACP, describes the role of the pharmacist at the time of discharge for heart failure patients.
how-pharmacists-can-promote-behavioral-health
Theodore Pikoulas, PharmD, BCPP, the Associate Director of Behavioral Health Pharmacy Programs for Community Care of North Carolina, discusses how pharmacists can promote behavioral health in their daily practice.
how-independent-pharmacists-can-improve-their-bottom-line
Dan Benamoz, RPh, President and CEO of Pharmacy Development Services, discusses how independent pharmacists can improve their bottom line.
risk-factors-for-obesity
Seena Haines, PharmD, BCACP, FAPhA, FASHP, BC-ADM, CDE, professor and department chair for Pharmacy Practice, University of Mississippi School of Pharmacy, outlines some risk factors for obesity.
sglt2-inhibitors-and-risk-for-ketoacidosis-and-urinary-tract-infections-
Susan Cornell, PharmD, CDE, FAPhA, FAADE, describes the risks for ketoacidosis and serious urinary tract infection associated with use of SGLT2 inhibitors.
$AD300x250BB$
Latest Issues
$auto_registration$